Department of Neurological Sciences, Dino Ferrari Center and Center of Excellence on Neurodegenerative Diseases, University of Milan, IRCCS Ospedale Maggiore Policlinico, via F Sforza 35, 20122 Milan, Italy.
Expert Rev Neurother. 2003 Sep;3(5):619-30. doi: 10.1586/14737175.3.5.619.
Alzheimer's disease is the most common neurodegenerative disorder and most prevalent cause of dementia in the elderly. Current standard treatment of Alzheimer's disease is based on the use of acetylcholinesterase inhibitors, which have shown symptomatic benefits on cognitive, functional and behavioral symptoms of the disease. A growing body of evidence suggests that the accumulation of amyloid beta-peptides may play a pivotal role in the pathogenesis of Alzheimer's disease (amyloid hypothesis). The incremental progress in elucidating the molecular basis of Alzheimer's disease is pointing the way towards more targeted and pathogenically specific treatment approaches. This review analyzes the available data on the new directions of Alzheimer's disease therapy, with particular focus on secretase inhibitors, amyloid beta-peptide vaccination,anti-inflammatory agents, metal chelators and cholesterol-lowering drugs.
阿尔茨海默病是最常见的神经退行性疾病，也是老年人中最常见的痴呆症病因。目前，阿尔茨海默病的标准治疗基于乙酰胆碱酯酶抑制剂的使用，这些抑制剂已显示出对疾病的认知、功能和行为症状有症状改善作用。越来越多的证据表明，β-淀粉样肽的积累可能在阿尔茨海默病的发病机制中起关键作用（淀粉样蛋白假说）。在阐明阿尔茨海默病的分子基础方面取得的进展为更有针对性和更具致病性的治疗方法指明了方向。本综述分析了阿尔茨海默病治疗新方向的现有数据，特别关注了分泌酶抑制剂、β-淀粉样肽疫苗、抗炎药、金属螯合剂和降胆固醇药物。
